In addition, among the patients with wild type EGFR which account for more than 50% of NSCLC patients, docetaxel- or cisplatin-based chemotherapy remains the first-choice treatment strategies regardless of significant adverse effects14. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.